Clinical Features, Microbial Profiles, and Antimicrobial Resistance in Neonates

Overview

This study investigates the clinical characteristics and antimicrobial resistance profiles of neonatal bloodstream infections (BSIs) caused by ESKAPEEc pathogens in Southwest China. It highlights the significant prevalence of these pathogens and the associated challenges in treatment due to rising antimicrobial resistance.

Background

Neonatal BSIs are a critical health issue, with high morbidity and mortality rates. The rapid progression of these infections necessitates timely diagnosis and treatment to prevent severe outcomes. Understanding the microbial profiles and resistance patterns of pathogens like ESKAPEEc is essential for guiding effective empirical antibiotic therapy in neonates.

Data Highlights

No numerical data available in the provided source material.

Key Findings

• Neonatal BSIs are complicated by high morbidity and mortality, with case fatality rates up to 19%.
• ESKAPEEc pathogens account for 58.6%-76.3% of BSIs in neonates.
• Antimicrobial resistance among ESKAPEEc pathogens limits treatment options and complicates management.
• Early-onset sepsis (EOS) and late-onset sepsis (LOS) are defined based on the timing of infection relative to birth.
• Prompt investigation of ESKAPEEc pathogens and their resistance profiles is critical for improving clinical outcomes.

Clinical Implications

Healthcare professionals should prioritize early diagnosis and appropriate empirical antibiotic therapy for neonates suspected of having BSIs. Awareness of local microbial profiles and resistance patterns is crucial for optimizing treatment strategies and improving patient outcomes.

Conclusion

The study underscores the urgent need for ongoing surveillance of ESKAPEEc pathogens in neonatal BSIs to inform clinical practice and combat antimicrobial resistance effectively.

References

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Recommendations | Neonatal infection: antibiotics for prevention and treatment | Guidance | NICE
6. IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
7. Landmark clinical trial for improving treatment options for newborns with sepsis to include nine countries | GARDP
8. Recommendations | Neonatal infection: antibiotics for prevention and treatment | Guidance | NICE
9. IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
10. Landmark clinical trial for improving treatment options for newborns with sepsis to include nine countries | GARDP